We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Constellation Healthcare Technologies | LSE:CHT | London | Ordinary Share | CMN SHS USD0.0001 (DI/REG S) |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 216.00 | 0.00 | 01:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| - |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 216.00 | GBX |
Constellation Healthcare (CHT) Share Charts1 Year Constellation Healthcare Chart |
|
1 Month Constellation Healthcare Chart |
Intraday Constellation Healthcare Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 02/4/2021 | 18:16 | ****** CHARTS ****** | 11 |
| 31/1/2020 | 13:36 | Constellation Healthcare Technologies | 950 |
| 03/3/2010 | 21:24 | Company Health Group | 220 |
| 08/10/2007 | 19:47 | Company Health Group - The New Name In Town. | 188 |
| 26/8/2006 | 12:03 | Company Health with Charts & News | 1 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 05/7/2019 10:17 by stuffee Just to cheer everyone up, I've been told that Orion has now filed an amended complaint challenging the previous decision that Nominee registered shareholders (and ultimately the beneficial owners) would not be liable for damages. I fear this might bring us all back into the firing line. Advise any vulnerable former CHT shareholders to seek legal advice; I've appointed WilmerHale, who seem sensible and are now advising several former shareholders. |
Posted at 11/10/2018 09:16 by stuffee LITIGATION AGAINST FORMER SHAREHOLDERSI have just received the extraordinary news that Orion, the vehicle that bid for Constellation two years ago, is taking legal action against the former CHT shareholders to recover all the consideration paid. It claims that due to the fraud undertaken by Paul Parmar, former CEO, and his pals, CHT was worthless when it bid and is therefore claiming against former shareholders. I think such action against public unconnected former shareholders is unprecedented but there is a threat to recover assets from anyone who ignores the action. At present the claim is against the registered nominee shareholders, but in due course they will no doubt attempt to claim against the beneficial owners. Interesting if there is any comment from finnCap, who advised CHT and recommended us to accept the bid. Similarly I believe KPMG undertook due dili on CHT. We need urgent legal advice on this but it is obviously uneconomic to seek advice individually. Is anyone else aware of this pending action and have they appointed any advisers? |
Posted at 20/3/2018 13:53 by quantdragon66 WOW real sad !!!! this certainly does not read right ! why do I feel that I have read the same story a few times before CC Capital came in as a lead investor with their acquisition of CHT. I need to look at past stories, this here sounds like crazy movie story. I also met Parmar and CHT at a group breakfast and did not feel the project CHT was a fraud. I thought Parmar was direct, intelligent, good command over the project and its detail, handled the questions very well, impatient, and even arrogant but did not feel he was a fraud, there is something else here. What a mess, Shocking to say the least. This definitely does not feel right at all I have a gut feeling there is more to this story. |
Posted at 11/10/2017 08:23 by rivaldo Intriguing stuff FYI from yesterday re CHT, Parmar etc.....I'll copy the whole article as the FT might go subscription-access only at some point:"Ex-Blackstone dealmaker stumbles in first solo acquisition Chinh Chu’s healthcare group Constellation said to face potential cash crunch Financier Chinh Chu’s first solo acquisition was supposed to be a quick reorganisation and initial public offering for his newly established private fund, CC Capital Management.Instead, it has become a corporate turnround challenge for the former top Blackstone Group dealmaker, according to people familiar with the situation. Mr Chu’s firm acquired Constellation Healthcare, a group rolling up medical back-office companies, at the end of 2016 for approximately $309m. His plan was to reorganise what was previously a London Aim-listed company and take it public in the US, where its business is based. But now he must determine how much Constellation is actually worth, as the company faces a potential cash crunch, according to those people. The concerns about cash arose after a late September discussion between the board and Constellation’ It was not immediately clear which transactions the board had found troublesome, or how they led to the firm’s unexpected potential worries about cash. The company was a buyout vehicle for small, private healthcare billing and back-office operations, with an opaque ownership structure. The Constellation case underscores the difficulty of finding new investments when valuations are rising in both public and private markets. In September, private equity firms were holding an industry record $942bn of uninvested money, according to Preqin Ltd. Medical back-office businesses offer an alluring pitch for firms looking to deploy such capital: that government policy is driving broad changes in the way doctors’ businesses are managed, which are expected to insulate such firms from economic downturns. The acquisition of Constellation was Mr Chu’s first independent deal after leaving private equity giant Blackstone in late 2015. CC Capital is a co-manager of special purpose acquisition company CF Corp, a publicly traded “blank cheque” company that raised $600m in its 2016 IPO.Despite his big-ticket financial career, Mr Chu has attracted little publicity over the years. In contrast, Mr Parmar’s record has been colourful and, at times, controversial. He took to the airwaves in 2008 to publicise his 32-acre property in New Jersey, offering viewers of ABC’s Nightline programme a personal tour of the residential compound. Two years later Mr Parmar’s lender, Deutsche Bank, filed a foreclosure action in New Jersey. The $23.7m mortgage was eventually restructured and reassigned to an entity called Aquila Alpha, which filed its own foreclosure action against Mr Parmar last year. Mr Parmar confirmed in a message to the Financial Times that he was expected to step down from his role as chief executive of Constellation ahead of an envisioned IPO. He also denied any problem with the company’s cash flow, but did not provide any additional proof or documentation of the company’s cash position by press time. The first of his responses, sent through a messaging app, was sent under the name “Marc Antony”. CC Capital offered outside investors a mix of cash and payment-in-kind-type notes rolling up interest annually, at 3 percentage points above 3-month US Libor, according to Bloomberg data — that would give the notes a yield of nearly 4.5 per cent. The transaction was partially funded by BofA Merrill Lynch, according to the proxy statement sent to shareholders. " |
Posted at 18/8/2017 09:57 by gary1966 Thanks stuffee. Managed to find a copy of the initial takeover RNS and looks as though you are correct in that interest is payable at 5%pa but accrues until repayment of notes. Here is the relevant section.The Promissory Notes shall accrue payment-in-kind (PIK) interest at an annual rate of 5 per cent., be payable by CHT or Parent (or an intermediary holding company between the Surviving Corporation or Parent) on or prior to the date that is the seventh anniversary of the issuance date, will be unsecured, will not be registered for listing or trading and will be subject to typical transfer restrictions. If any CHT Shareholder does not sign a Voting Agreement which contains a release of claims under the laws of the State of Delaware, the value of its Promissory Notes may reduce in certain circumstances as described in this announcement. |
Posted at 23/2/2017 14:31 by parmared off Part 6 :PART 6TAXSECTION A: UNITED KINGDOM TAX CONSEQUENCESThe following paragraphs are intended as a general guide only and are based on current UK legislation and HM Revenue and Customs practice (which is subject to change and possibly with retrospective effect) and are not exhaustive. They summarise advice received by the CHT Directors as to the position of Shareholders who (unless the position of non resident Shareholders is expressly referred to) are resident (and domiciled) in the United Kingdom ("UK") for tax purposes, who are the absolute beneficial owners of their Common Shares and who hold their Common Shares as an investment. The discussion does not address all possible tax consequences relating to an investment in Common Shares. Certain Shareholders, such as dealers in securities, employees and officers, Shareholders that are exempt from taxation, insurance companies and collective investment vehicles, may be taxed differently and are not considered.IF YOU ARE IN ANY DOUBT AS TO YOUR TAX POSITION OR YOU ARE SUBJECT TO TAX IN A JURISDICTION OUTSIDE THE UK, YOU SHOULD CONSULT AN APPROPRIATE PROFESSIONAL ADVISER WITHOUT DELAY.Taxation of Chargeable GainsLiability to UK taxation of chargeable gains will depend on the individual circumstances of Shareholders. Where a Shareholder receives the Acquisition Price, this will take the form of cash and Promissory Notes. The tax treatment of each of these elements of consideration will be different.CashThe receipt of the cash consideration will constitute a part disposal by that Shareholder of his or her Common Shares for the purposes of UK taxation of chargeable gains. Such a disposal may give rise to a liability to UK tax on chargeable gains depending on the Shareholder's circumstances (including the availability of exemptions, reliefs or allowable losses). The gain will be calculated by reference to the part disposal of the Common Shares by that UK Shareholder, the remainder of the Common Share being treated as exchanged for the Promissory Notes as detailed below.In the case of individual Shareholders who suffer a charge to UK capital gains tax, there are two main rates of UK capital gains tax, the applicable rate will be dictated by the individual Shareholders' amount of taxable income. Those individual Shareholders who are higher rate or additional rate taxpayers will pay capital gains tax at 20 per cent. and other individual Shareholders will pay capital gains tax at 10 per cent. Entrepreneurs' relief may be available for the first £10 million of cumulative lifetime gains realised on or after 6 April 2011. Different thresholds apply to gains made before this date. Where entrepreneurs' relief applies, gains which are within the relevant lifetime allowance are taxed at 10 per cent. even if the Shareholder is a higher rate or additional rate taxpayer. Gains made in excess of the lifetime limit are subject to capital gains tax at the prevailing rate, currently 10 per cent. or 20 per cent. as indicated above.For Shareholders who are within the charge to UK corporation tax (but who do not qualify for the substantial shareholdings exemption in respect of their Common Shares) the rate of UK corporation tax is currently 20 per cent. In addition, for such Shareholders indexation allowance on the acquisition cost of the Common Shares should be available until the date of disposal of the Common Shares. Indexation allowance increases the acquisition cost of an asset for tax purposes in line with the rise in the retail prices index and thus reduces the amount of the chargeable gain on disposal of the asset. Indexation allowance cannot be used to create or increase a loss.59A Shareholder who is not UK resident will not be subject to UK tax on a gain arising on the disposal of Common Shares unless either (i) the Shareholder carries on a trade, profession or vocation in the UK through a branch, permanent establishment or agency and, broadly, holds the Common Shares for the purposes of the trade, profession, vocation, branch or agency or (ii) the Shareholder falls within the anti avoidance rules applying to temporary non residents.Shareholde |
Posted at 23/2/2017 14:24 by parmared off 16. TaxationYour attention is drawn to Part 6 of this Proxy Statement, which contains a general guide as to the UK and US tax implications for Shareholders as a result of the Acquisition. If you are in any doubt as to your own tax position, or if you are subject to taxation in any jurisdiction other than the UK and US, you should consult an appropriate independent and legal and tax advisor.The ultimate beneficial owner of the relevant Common Shares is asked to complete and validly execute the applicable Tax Forms which may be downloaded from the Company's website at www.constellationhea |
Posted at 23/1/2017 14:16 by actofwill Shareholders will be regarded for US tax purposes as receiving a portion of the Acquisition Price per Common Share ($1.74 of the cash Acquisition Price and the $0.43 in Promissory Notes, totalling $2.17 per Common Share) in redemption of a portion of their Common Shares (“Redemption Consideration” |
Posted at 29/11/2016 13:06 by mr_benn Investors Chronicle verdict:It's fair to say that corporate activity has been a major feature of my watchlist of small-cap shares in the past few years. It shows no signs of waning, eitherAim-traded shares in Constellation Healthcare Technologies (CHT:222p), a provider of outsourced medical billing services to US physicians, soared on Friday last week after the company announced a merger agreement with a vehicle backed by its chief executive Paul Parmar and CC Capital, a privately-owned investment company. The offer consists of a cash payment of 293¢, equivalent to 235.5p at current exchange rates, and a promissory note worth 43¢, or 34.5p a share, which combined values the fully diluted equity of the company at $308m (£248m), representing a 45 per cent premium to Constellation's previous closing share price.Analyst Guy Hewett at house broker finnCap has suspended coverage after the announcement, but was previously forecasting a $10.2m increase in cash profit to $52.6m based on a $17.7m rise in revenue to $150.3m in 2017, reflecting the upside of acquisitions made in the past 12 months. On this basis, the exit multiple represents just under six times cash profit forecasts to enterprise value, and around 13 times adjusted EPS of 26.9¢ (21.6p).Shares in Constellation initially surged pass the 250p target price I outlined when I initiated coverage at 178p last month ('Constellation's brightening prospects', 10 Oct 2016), but have since drifted back to a bid-offer spread of 215p to 222p. There are several reasons for this.Firstly, the Parmar controlled entities holding 53.5 per cent of the shares will effectively take a 49.3 per cent economic interest in the new bid vehicle, and that's after banking profit on 38 per cent of its shareholding in Constellation, so the chief executive is keeping virtually all his skin in the game. That's not the case for minority shareholders whose only interest in the new bid vehicle will be the payment-in-kind (PIK) promissory note, the terms of which are hardly overly generous: it's unsecured and unlisted; accrues interest at a paltry rate of 5 per cent a year and repayable on or prior to the seventh anniversary of their issuance; and is denominated in US dollars, leaving UK holders exposed to currency risk.Secondly, if the merger agreement is terminated then under certain circumstances, which in my view are not onerous, Constellation will be liable to pay CC Capital's expenses of up to $4m, and potentially is in hock for a further $10m in the event that fewer than 89 per cent of Constellation shareholders vote in favour of the merger agreement. Moreover, if a higher offer is received from a rival bidder, then Constellation will have to pay CC Capital $8m plus expenses. There is a chance that enough minority shareholders may decide not to accept the offer and that could cost the company millions.Thirdly, the 293¢ a share cash consideration being offered to buy out the issued share capital of Constellation's minority shareholders, who control 46.5 per cent of the shares, will cost the bid vehicle $115.6m, effectively all of which is being funded by a new Bank of America Merrill Lynch credit facility arranged by the bidder. Constellation has an ungeared balance sheet, and could just as easily return cash to shareholders by gearing it up rather than ceding control to another party. Moreover, the promissory note is funding a chunky 13 per cent of the total consideration being offered, so to place a value of 34.5p a share on this unlisted paper is unrealistic in my view given the yield being offered and the terms of issue.Fourthly, although the 270p a share offer at current exchange rates is above my target price of 250p and is 51 per cent higher than the level at which I initiated coverage last month, it only represents a small bid premium above my fair value price when you value the PIK note using a more reasonable interest rate of 10 per cent. On this basis, I value the net present value of the note at only 25p in its current form and not 34.5p. Put simply, the cash consideration needs to be much higher than 235.5p a share, and the interest rate on the promissory substantially higher than 5 per cent for the offer to be worth backing. And that's why the shares are trading below the level of the 235.5p cash element of the offer as investors are clearly disinterested in holding an unsecured low-yielding PIK promissory note in a privately-owned Delaware bid vehicle.Of course, shareholders are being given the opportunity to vote on the merger agreement at the forthcoming general meeting and it will only proceed if sanctioned by those controlling at least 89 per cent of the share capital; by a majority of the minority shareholders; and by a majority of the aggregate voting power. Frankly, there is no way I can possibly suggest voting in favour of the merger arrangement in its current form and I will only change that view if it is sweetened to include a higher cash consideration, and a considerably higher interest rate on the unsecured and unlisted PIK notes. This would act as a major incentive for the bid vehicle to redeem the PIK notes as soon as possible, and realign the interests of minority shareholders with those of the bid vehicle, including Constellation's chief executive Paul Parmar. Reject the offer. |
Posted at 27/11/2016 20:26 by stuffee Battlebus, I feel if Parmar wants this gem, he must pay a fair price and don't feel it a waste of time to oppose.Parmar needs a "majority of the minority" to succeed. Legal & General own 5% and interesting that the bid announcement was silent on their intent. If Legals and a few others oppose, Parmar should be forced to pay a proper price with proper currency rather than massively overvalued Micky Mouse PIK prom notes. Interesting that finnCap, who are recommending us mug punters to accept so called 270p, recently valued CHT at 310p. Extract from comment on their recent research: "finnCap’s punchy price target The broker reckons the stock is worth 310p more than double the closing share price. It points out the business is trading on a forward multiple of less than 10 times earnings 8%-plus free cash flow." Traditionally bid prices are considered fair if priced at a premium to independent value. Regrettably there have been too many examples in recent years of management, who can properly review prospects, buying out minorities on the cheap and then realising excessive gains later. After all their efforts and costs, I doubt Parmar and pals are going to walk away if this bid is rejected. I am not too concerned by their threats of demanding termination payments from CHT to cover some of their costs bearing in mind they own over 53% of CHT themselves. I feel they must pay a proper price and, based on current information, I don't intend to let them steal my holding at less than 310p, payable in proper liquid currency. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
